Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 8/20 | 0.54 |
| ▸ | RAB9A | P51151 | 7/20 | 0.54 |
| ▸ | NPC1 | O15118 | 5/20 | 0.54 |
| ▸ | BCHE | P06276 | 3/20 | 0.54 |
| ▸ | LMNA | P02545 | 2/20 | 0.54 |
| ▸ | MAOB | P27338 | 4/20 | 0.53 |
| ▸ | PLIN1 | O60240 | 1/20 | 0.53 |
| ▸ | TNFRSF1A | P19438 | 1/20 | 0.53 |
| ▸ | ACHE | P22303 | 1/20 | 0.53 |
| ▸ | RECQL | P46063 | 1/20 | 0.53 |
| ▸ | PLIN5 | Q00G26 | 1/20 | 0.53 |
| ▸ | CYP1B1 | Q16678 | 1/20 | 0.53 |
| ▸ | ABHD5 | Q8WTS1 | 1/20 | 0.53 |
| ▸ | TYR | P14679 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.48 |
| ▸ | NFKB1 | P19838 | 3/20 | 0.48 |
| ▸ | NFKB2 | Q00653 | 3/20 | 0.48 |
| ▸ | RELA | Q04206 | 3/20 | 0.48 |
| ▸ | MEN1 | O00255 | 3/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27959814 | 1.00 | MAPT (0.54) | MAPTRAB9ANPC1BCHELMNA | |
| SCHEMBL29139875 | 0.85 | MAPT (0.53) | MAPTRAB9ANPC1BCHELMNA | |
| SCHEMBL14280370 | 0.82 | MAOB (0.57) | MAPTRAB9ANPC1BCHELMNA | |
| SCHEMBL9006476 | 0.82 | MAPT (0.69) | MAPTRAB9ANPC1BCHELMNA | |
| SCHEMBL11318866 | 0.81 | NFKB1 (0.40) | MAPTBCHELMNANFKB1SMN1; SMN2 | |
| SCHEMBL29367457 | 0.80 | TDP1 (0.46) | LMNAKMT2AMEN1SMN1; SMN2SENP7 | |
| SCHEMBL179742 | 0.80 | TDP1 (0.46) | LMNAKMT2AMEN1SMN1; SMN2SENP7 | |
| SCHEMBL11519765 | 0.80 | TDP1 (0.46) | LMNAKMT2AMEN1SMN1; SMN2SENP7 | |
| SCHEMBL179743 | 0.80 | TDP1 (0.46) | LMNAKMT2AMEN1SMN1; SMN2SENP7 | |
| SCHEMBL9121684 | 0.79 | MAPT (0.58) | MAPTRAB9ANPC1BCHELMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9078885-B2 | Respiratory disease treatment | PULMAGEN THERAPEUTICS (INFLAMMATION) LIMITED (GB) | 2015-07-14 | — | — | US | disclosed |
| US-20140248357-A1 | Respiratory Disease Treatment | PULMAGEN THERAPEUTICS (INFLAMMATION) LIMITED (GB) | 2014-09-04 | — | — | US | disclosed |
| US-8815837-B2 | Respiratory disease treatment | PULMAGEN THERAPEUTICS (INFLAMMATION) LIMITED (GB) | 2014-08-26 | — | — | US | disclosed |
| CN-103842066-A | Polymerizable inorganic particle dispersant, inorganic-organic composite particle containing the same, and inorganic-organic resin composite material | NIPPON KASEI CHEM | 2014-06-04 | — | — | CN | disclosed |
| EP-2222272-B1 | Respiratory disease treatment | PULMAGEN THERAPEUTICS INFLAMMATION LTD (GB) | 2012-11-07 | — | — | EP | disclosed |
| US-20120264787-A1 | Respiratory Disease Treatment | PULMAGEN THERAPEUTICS (INFLAMMATION) LIMITED (GB) | 2012-10-18 | — | — | US | disclosed |
| US-8236786-B2 | Respiratory disease treatment | PULMAGEN THERAPEUTICS (INFLAMMATION) LIMITED (GB) | 2012-08-07 | — | — | US | disclosed |
| WO-2011098746-A1 | CRYSTALLINE ACID ADDITION SALTS OF ( 5R) -ENANTI0MER OF PIOGLITAZONE | PULMAGEN THERAPEUTICS (INFLAMMATION) LIMITED (GB) | 2011-08-18 | — | — | WO | disclosed |
| US-20110053986-A1 | RESPIRATORY DISEASE TREATMENT | PULMAGEN THERAPEUTICS (INFLAMMATION) LIMITED (GB) | 2011-03-03 | — | — | US | disclosed |
| EP-2222272-A1 | RESPIRATORY DISEASE TREATMENT | Pulmagen Therapeutics (Inflammation) Limited (GB) | 2010-09-01 | — | — | EP | disclosed |
| WO-2010015818-A1 | RESPIRATORY DISEASE TREATMENT | ARGENTA DISCOVERY LIMITED (GB) | 2010-02-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120264787-A1 | Respiratory Disease Treatment | IL5, PPARD, PPARG | MAPT 3187/4885RAB9A 1239/4885NPC1 944/4885 |
| US-20140248357-A1 | Respiratory Disease Treatment | IL5, PPARD, SLC5A1 | MAPT 3141/4885RAB9A 1325/4885NPC1 915/4885 |
| US-20110053986-A1 | RESPIRATORY DISEASE TREATMENT | IL5, PPARD, PPARG | MAPT 3187/4885RAB9A 1239/4885NPC1 944/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.